PETALUMA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced today that the company will be presenting at the 4th Annual BIO InvestorForum Conference to be held October 9-11, 2007 at the Palace Hotel of San Francisco. The company's president and chief executive officer, Hoji Alimi, is scheduled to present an overview of the company, its clinical programs and the most recent quarter on Thursday, October 11 at 1:30 p.m. PDT (4:30 p.m. EDT) in the Sea Cliff room. For more information on this event please visit: http://www.investorforum.bio.org/.
To access a live audio and visual webcast of Mr. Alimi's presentation, please log on to Oculus Innovative Sciences' website at http://ir.oculusis.com/events.cfm approximately 30 minutes prior to the presentation in order to register and download any necessary software. The webcast will be available for 30 days at this website.
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a controlled slow-release solution containing active chlorine and other gases resulting in a biocompatible technology to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. The technology has demonstrated significant wound healing in chronic and acute wounds. It has been commercialized outside of the U.S. for the treatment of infected wounds. It is currently under evaluation for the treatment of mildly infected diabetic ulcers in the U.S.
Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is http://www.oculusis.com.
Oculus Innovative Sciences, Inc. The Ruth Group
Dan McFadden Sara Ephraim (investors)
Director of Public and (646) 536-7002
Investor Relations email@example.com
firstname.lastname@example.org Jason Rando/
Janine McCargo (media)
(646) 536-7025 / 7033
|SOURCE Oculus Innovative Sciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved